View Older Stories View More Recent Stories

Sep 14, 2023 08:01AM NovaBay Pharma (NBY) Announces Commercial Launch of Avenova Allograft
Sep 14, 2023 08:00AM NovaBay Pharmaceuticals Announces Commercial Launch of Avenova® Allograft
Sep 11, 2023 08:03AM NovaBay Pharma (NBY) Enters Agreement with BioStem Technologies (BSEM) to Commercialize Amniotic Tissue Allograft as Avenova Allograft
Sep 11, 2023 08:00AM NovaBay Pharmaceuticals Announces Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova® Allograft
Mar 7, 2023 07:30AM BioStem Technologies to Acquire Majority of Assets of Auxocell Laboratories, Inc.
Feb 14, 2023 08:55AM BioStem Technologies Enters Into a Share Exchange Agreement
Feb 1, 2023 07:30AM BioStem Technologies Poised for Growth with Two New Hires: Michael Sylvester Joins as Vice President of Sales, Neal Bhattacharya as Vice President of Marketing
Dec 16, 2022 07:30AM BioStem Technologies Announces Up-Listing to the OTCQB Venture Market
Oct 10, 2022 07:30AM BioStem to Present at the Dawson James Securities 2022 Small Cap Growth Conference
Sep 13, 2022 07:30AM BioStem Announces Publication of a Standardized Method to Evaluate Growth Factor Elution from Placental Tissue Allografts
Aug 16, 2022 07:30AM BioStem Technologies to Host Second Quarter Financial Results and Corporate Update Conference Call on August 22nd
Apr 1, 2022 10:00AM BioStem Technologies Inc. Reports December 31, 2021 Year End Financial Results
Jul 27, 2021 09:00AM BioStem Technologies, Inc., Announces the Engagement of Biologics Consulting To Support FDA Strategies and Submissions.
Apr 20, 2021 09:00AM BioStem Technologies, Inc., Announces the Addition of Three Key Scientific Advisory Board Members
Mar 15, 2021 09:00AM BioStem Technologies Engages D. Brooks & Associates for 2020 and 2019 Audit
Dec 24, 2020 02:00PM BioStem Technologies, Announces Filing of 2020 Quarterly Reports
Aug 11, 2020 09:00AM BioStem Life Sciences Signs Manufacturing Agreement for Amniotic Membrane Allograft Platform
Jul 15, 2020 09:00AM BioStem Life Sciences Receives Accreditation by The American Association of Tissue Banks® (AATB®)
Jun 26, 2020 09:00AM BioStem Technologies, Inc. Announces Tissue Bank Certification in California and Maryland
Apr 29, 2020 12:35PM BioStem Technologies Announces Corporate Update on Company Direction
Mar 27, 2020 05:00PM BioStem Life Sciences Announces ISBT 128 Registration via ICCBBA
Mar 13, 2020 09:30AM BioStem Life Sciences Announces Expansion; Contract Manufacturing Capabilities, and Research and Development Laboratory
Oct 17, 2018 08:00AM BioStem Technologies Selects PCG Advisory Group for Investor Relations and Strategic Communications
Oct 1, 2018 10:45AM BioStem Life Sciences, Inc., Subsidiary of BioStem Technologies, Inc., Announces Entry into Market with Four Amniotic Products
Sep 19, 2018 09:00AM BioStem Technologies Inc. to Present at The MicroCap Conference on October 1st and 2nd in New York City at the Essex House
Sep 17, 2018 10:43AM Nesvik Pharmaceuticals, Inc., a Subsidiary of BioStem Technologies, Inc., Announces Engagement of The Gnomon Group for Pre-Investigational New Drug Application Strategy
Aug 28, 2018 10:10AM Nesvik Pharmaceuticals, Inc., Receives Updated U.S. FDA Establishment Registration in Light of New Product Development
Aug 17, 2018 09:30AM BioStem Technologies, Inc. Completes 2016, 2017 Audit of Financial Statements
Aug 15, 2018 09:00AM BioStem Technologies, Inc. Engages Maxim Group LLC For Strategic Advisory Services
Aug 9, 2018 09:00AM BioStem Technologies, Inc. (BSEM) Launches New Subsidiary to Engage in the Processing and Supply of Regenerative Tissue Products
Aug 8, 2018 09:00AM BioStem Technologies Inc. Launches Expanded Shareholder Communications Initiative
Jul 19, 2018 09:00AM BioStem Technologies (BSEM) Subsidiary Nesvik Pharmaceuticals Announces the Completion of An Asset Purchase of Multiple New Drug Compounds and Launches Joint Development Venture with CCM Pharma Soluti
Jun 18, 2018 05:30PM BioStem Technologies Inc. Announces Issuance of Drug Enforcement Administration Registration for Qualified Pharma Ingredients
Apr 4, 2018 10:28AM BioStem Technologies Inc. Enters Into Consulting and Advisory Agreement with Dr. Irmgard Huber
Mar 26, 2018 07:22PM BioStem Technologies, Inc. Announces Letter of Intent with CCM Pharma Solutions to Co-Develop Multiple Solid to Liquid Dose Drugs Through 505(b)(2) Accelerated FDA Approval Process
Mar 13, 2018 06:16PM BioStem Technologies Inc. Announces Engagement of Dr. Felix Amon for Pharmaceutical Business Development
Mar 9, 2018 05:09PM BioStem Technologies Inc. Enter into Agreement with Barbara Krutchkoff, PhD. To Guide Scientific Affairs
Feb 16, 2018 09:44AM BioStem Technologies Inc. Applies for Uplisting to the OTCQX Market
Feb 9, 2018 10:39AM BioStem Technologies Inc. Announces New Transfer Agent, V Stock Transfer
Feb 8, 2018 05:00PM BioStem Technologies Adds Chief Revenue Officer to Executive Team
Jan 26, 2018 09:45AM BioStem Technologies, Inc. Announces the Engagement of Investment Banking Firm Young America Capital for 15 Million Dollar 506(c) Offering.
Jan 24, 2018 10:05AM BioStem Technologies Inc. Announces New Board Member, Dr. Jennie Sandqvist
Dec 11, 2017 09:43AM BioStem Technologies Inc. Announces a Pre-Clinical Study of BSEM17-115 at University of Miami
Dec 1, 2017 03:05PM BioStem Technologies, Inc. Announces the Addition of University of Miami Professor Brant D. Watson, Ph.D., to the Company’s Scientific Advisory Board
Nov 7, 2017 09:00AM BioStem Technologies, Inc. Launches SEO Optimized Website and Facility Expansion to Include Schedule III-V DEA Product Storage
Nov 1, 2017 12:26PM BioStem Technologies, Inc. Files “Issuer Company-Related Action Notification” with the Financial Industry Regulatory Authority, Requesting Name and Symbol Change to BioBlue Technologies
Jun 9, 2017 09:00AM BioStem Technologies, Inc. Announces Letter of Intent with Watermakers, Inc. to begin testing on Staniel Cay in the Exuma Cays, Bahamas
Apr 6, 2017 10:25AM BioStem Technologies Inc. (OTC PINK: BSEM) Announces Audit Process and Uplisting Plans to the OTCQX Market
Mar 27, 2017 09:30AM BioStem Technologies, Inc. Announces Issuance of Prescription Drug Repackager Permit for Qualified Pharma Ingredients Inc.
Mar 24, 2017 02:18PM BioStem Technologies, Inc. Announces Completion of 503b Pharmaceutical and Stem Cell Research Laboratory
View More Recent Stories View Older Stories